ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1
Recce Pharma announces further positive data on RECCE 327 Cynata says results from Phase 1 will be released in Q1 2024 Recce Pharma shares [more…]
Top 10 at 10: $180m REE deals and one very upset oil and gas play
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. [more…]
Wisr survey reveals Aussies feel financial strain, yet daily coffee remains priority
National survey by fintech lender Wisr show Aussies are feeling rising costs of living 39% of respondents indicate groceries are exerting the most pressure on [more…]
Market Highlights: Wall Street keeps climbing; and the implications for chatbots as NYT sues OpenAI
ASX200 to open higher on Thursday, tracking Wall Street’s gains Apple wins court victory to pause the US government import ban The implications for chatbots [more…]
Check Up: The reason people quit weight-loss drugs
People are reportedly quitting popular weight loss drugs Ozempic and Wegovy after 3 months Side effects such as loss of muscle mass is one big [more…]
Google’s Gemini AI Demo: A Closer Look at the Edited Viral Video
The artificial intelligence (AI) world was recently abuzz with Google’s Gemini AI demo, a video that garnered 1.6 million views on YouTube, showcasing the AI’s [more…]
When Lambo? BetaShares crypto ETF smashes the rest to climb 200pc in 2023
BetaShares Crypto Innovators ETF (ASX:CRYP) surges 200% YTD, to be top 2023 performer Best performing ETFs in 2023 didn’t correlate with popular ETFs purchased by [more…]
Navigating Retirement: A Guide to Gratitude and Growth in 2023
2023 has unfolded as a year of significant opportunities and positive changes for retirees and those planning for retirement. Amidst economic fluctuations, this year has [more…]
ASX biotechs with big catalysts in 2024: Part 2
Avita Medical is expecting to have its RECELL Go marketing application approved by US FDA in May 2024 AI-focused medtech company Artrya expects its predicate [more…]
ASX biotechs with big catalysts in 2024: Part 2
Avita Medical is expecting to have its RECELL Go marketing application approved by US FDA in May 2024 AI-focused medtech company Artrya expects its predicate [more…]
